United States
Include All CSL Behring Country Sites

CSL Behring Makes Annual Start-Up Grants Available to Next Generation of Coagulation Researchers

Awards Named in Honor of Professor Norbert Heimburger, Pioneer of Modern Coagulation Research

Geneva, Switzerland — 09 July 2007

CSL Behring, a global leader in the protein biotherapeutics industry, announced today at the International Society on Thrombosis and Haemostasis (ISTH) XXIst Congress that it will award five annual grants to support new research projects in the area of coagulation. The start-up grants of 20,000 euros each ($26,780 U.S) will be awarded to young medical researchers for preclinical and/or clinical coagulation projects based on the scientific merit of their work.

The grant is named in honor of Professor Norbert Heimburger, a pioneer of modern coagulation therapy and a CSL Behring employee for over three decades. Among his many achievements was the development of virus-safe plasma products based on pasteurization. Due to his research efforts, Behring launched the first effectively virus-inactivated FVIII concentrate in 1981.

“CSL Behring is committed to advancing research that furthers our understanding of coagulation and improves the treatment of bleeding disorders such as hemophilia and von Willebrand disease,” said Roland Martin, Head of Research and Development at CSL Behring. “Supporting the next generation of specialists to medically and scientifically establish themselves is important to have continued progress in this therapeutic area.”

Grant applications must be received by February 1, 2008. They will be reviewed by a special selection committee of four scientifically renowned clinicians in the coagulation field: Erik Berntorp, MD, PhD, Malmö University Hospital, Sweden; Jorge DiPaola, MD, Great Plains Regional Hemophilia Treatment Center, USA; David Lillicrap, M.D., FRCPC, Queen’s University, Canada; and Johannes Oldenburg, M.D. PhD, University of Bonn, Germany.

For more information regarding the Professor Norbert Heimburger Grant and specific criteria for applications, please go to www.cslbehring.com/ProfHeimburgerAward.

About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about saving and improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of rare diseases such as immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.com.

Sheila A. Burke, Director, Communications & Public Relations
Worldwide Commercial Operations
CSL Behring

CRP16-05-0001 05/2016
© 2016 CSL Behring